ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "KYTHERA Biopharmaceuticals, Inc." (KYTH) Report Updated: Sep 29, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"KYTHERA Biopharmaceuticals, Inc." (KYTH)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Biotechnology
Competitors: MACK, ENTA, CBPO, RGEN

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: D down downgrade
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

"KYTHERA Biopharmaceuticals, Inc."© quotemedia

Company Profile

KYTHERA Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription products for the aesthetic medicine market. Its product candidate, ATX-101, is an injectable drug in Phase III clinical development for the reduction of submental fat. The company also has various additional research programs around therapeutic intervention for hair loss; and maintains active research interest in hair and fat biology, pigmentation modulation, and facial contouring. It has a collaboration arrangement with Bayer Consumer Care AG and a related collaboration agreement with Bayer Consumer Care AGs affiliate, Intendis GmbH to develop and commercialize ATX-101 outside the United States and Canada. The company was formerly known as AESTHERx, Inc. and changed its name to KYTHERA Biopharmaceuticals, Inc. in July 2006. KYTHERA Biopharmaceuticals, Inc. was founded in 2004 and is headquartered in Calabasas, California.

Recent News: "KYTHERA Biopharmaceuticals, Inc."